Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective
- 17 February 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 17 (4) , 335-345
Abstract
Introduction: Hematologic toxicity is an important side effect occurring in patients affected with anal cancer, undergoing combined radio-chemotherapy, with consistent clinical meaningfulness. Areas covered: Since more than a half of bone marrow is comprised within the pelvic region, the radiation dose received by this functional compartment is crucial. Modern imaging modalities may provide a useful tool to identify bone marrow and new delivery technology may enhance the radiation oncologist’s possibility to selectively spare these structures, potentially decreasing acute hematologic toxicity profile in this setting. Expert commentary: Correlation between dose to pelvic structures and acute hematologic toxicity has been studied in several oncological settings, mainly on a retrospective frame. Different dose metrics were found to be correlated including mean doses and different points within the dose–volume histogram ranging from low to medium-high doses. Several imaging modalities were used to identify bone marrow both morphological and functional. Several clinical endpoints were used. In general, accounting for bone marrow during the treatment planning process may be important to decrease the acute hematologic toxicity profile during concurrent chemo-radiation in anal cancer patients. The most appropriate strategy to address this issue need further investigation and deserve validation in a prospective clinical framework.Keywords
This publication has 63 references indexed in Scilit:
- Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canalPractical Radiation Oncology, 2014
- Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 TrialJournal of Clinical Oncology, 2012
- IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer CenterRadiation Oncology, 2012
- 3’-deoxy-3’-[18F]fluorothymidine PET Quantification of Bone Marrow Response to Radiation DoseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter ExperienceJournal of Clinical Oncology, 2007
- Structural and Functional Imaging of Normal Bone Marrow and Evaluation of Its Age-Related ChangesSeminars in Nuclear Medicine, 2007
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996
- Active bone marrow distribution as a function of age in humansPhysics in Medicine & Biology, 1981
- The Distribution of Active Bone Marrow in the AdultPhysics in Medicine & Biology, 1961